

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	KLOBCAR ET AL.	)	
SERIAL NO.:	10/599,154	)	EXAMINER: HUANG, GIGI
FILED:	JANUARY 11, 2007	)	GEORGIANA
TITLE:	PROCESS FOR PREPARING A SOLID	)	ART UNIT: 1612
	PHARMACEUTICAL COMPOSITION	)	CONFIRMATION NO.: 5071

**VIA EFS**

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(i) the relevance of EP 0309324; EP 1400531; EP 1403278 and DE 197 21 290, is set forth in their abstracts, the English translations of which are provided. The relevance of the remaining foreign applications is as set forth in the following table.

Foreign Citation	Date	Country	US relevance
037231	01/28/1987	EP	US4350704; US4425355
049658	06/13/1984	EP	US4508729
0308340	03/13/1991	EP	US4902817
0308341	12/12/1990	EP	US4914214
0308339	05/06/1992	EP	US4935525, US4954640
1323729	11/03/2004	EP	US660288
1338591	08/27/2003	EP	US7157484
1362845	11/19/2003	EP	US2006252958
WO 2001/56353	08/09/2001	WO	US6818788
WO 2001/56972	08/09/2001	WO	US6774259
WO 2001/58868	08/16/2001	WO	US6835843
WO 2001/87835	11/22/2001	WO	US2003186896, US2005059609
WO 2001/87836	11/22/2001	WO	US2004029813, US2005203165
WO 2001/83439	11/08/2001	WO	US2003158121, US2004248817
WO 2003/064388	08/07/2003	WO	US2005119492
WO 2003/087050	10/23/2003	WO	US6696481
WO 2004/075889	09/10/2004	WO	US2006276659

### TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents and publications are believed of interest herein and consideration and citation of as interest by the Examiner is respectfully requested.

The undersigned hereby authorizes the charge of \$180 in accordance with 37 CFR §§1.97(c) and 1.17(p) or any deficiency of fees submitted herewith to Deposit Account No. 19-5117.

Respectfully submitted,

Date: September 3, 2008

/Rosemary Kellogg/  
Rosemary Kellogg, #39,726  
Swanson & Bratschun, L.L.C.  
8210 Southpark Terrace  
Littleton, CO 80120  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

S:\CLIENTFOLDERS\0183 (UEXKULL & STOLBERG)\09\IDS 03.DOC